Emmaus Life Sciences, Inc. · OTC:EMMA
Emmaus Life Sciences — MYnd Analytics — Investor Presentation (June 2019)
25 slides from Emmaus Life Sciences's investor presentation, Jun 20, 2019
Slide 1: June 2019 Investor Presentation
A BEHAVIORAL HEALTH COMPANY THAT UTILIZES TOOLS AND TECHNOLOGY TO IMPROVE ACCESS TO CARE AND REDUCE TRIAL AND ERROR PRESCRIBING IMPROVING OUTCOMES AND LOWERING COSTS June 2019 Investor Presentation NASDAQ: MYND
Slide 2: Disclaimer
Investor Presentation DISCLAIMER This presentation contains “forward - looking statements” pursuant to the safe - harbor provisions of the Private Securities Litigation Reform Act of 1995 that include information relating to future events, future financial performance, strategies, expectations, comp
Slide 3: MYnd Analytics (NASDAQ:MYND)
Investor Presentation 3 MYND ANALYTICS (NASDAQ:MYND) MYnd Analytics provides technology and services that improve access to behavioral health resources through telemedicine and an artificial intelligence platform that allows clinicians to deliver personalized treatment plans. These solutions improve
Slide 4: Behavioral Health Crisis
Investor Presentation US Worldwide Estimated prevalence of depression 1 1.1 Billion Worldwide 90 Million U.S. 300 Million Worldwide 30 Million U.S. 30 Million Worldwide 3 Million U.S. Only 10% that seek treatment achieve remission 2 Only 27% Receive Treatment 1 BEHAVIORAL HEALTH CRISIS 1. Demyttenae
Slide 5: Trial and Error Prescribing Is Inefficient and Costly
Investor Presentation 80% of antidepressants are prescribed by Primary Care 1 Primary Care Primary Care Trial and Error Prescribing 10 % Remission Referred to Psychiatric Care Psychiatric Trial and Error Prescribing Med RX Patient Reaction Med Check 5 “TRIAL AND ERROR” PRESCRIBING IS INEFFICIENT AND
Slide 6: Government and Private Payers Are Enacting Programs to Close Gaps
Investor Presentation 6 GOVERNMENT AND PRIVATE PAYERS ARE ENACTING PROGRAMS TO CLOSE GAPS Expanding coverage • New government mandates have helped drive reimbursement for solutions that improve outcomes and reduce costs o Federal Mental Health Parity Act (2008) o Expansion Benefits for Medicare (200
Slide 7: MYnd Solves the ABCs of Behavioral Health
Investor Presentation MYND SOLVES THE ‘ABC ’s OF BEHAVIORAL HEALTH Challenge MYnd Analytics Solution Beneficiary A ccess Limited access to behavioral health specialists. Arcadian Telepsychiatry provides access to a national network of psychiatric providers, therapists and social workers through a cl
Slide 8: Trial and Error Prescribing
Investor Presentation TRIAL AND ERROR PRESCRIBING Primary care physicians have diagnostic tools and defined care protocols for treating chronic conditions like heart disease, diabetes and asthma 1 . • Primary care physicians regularly use EKGs to treat their patients that are at risk for cardiac con
Slide 9: PEER Utilizes Machine Learning to Develop Predictive Algorithms
Investor Presentation 9 PEER UTILIZES MACHINE LEARNING TO DEVELOP PREDICTIVE ALGORITHMS • An electroencephalogram (EEG) is a completely painless, non - invasive test that can be easily administered in a primary care environment. • The EEG records your brain’s electrical activity and provides a basis
Slide 10: PEER Online Provides Clinical Decision Support for Primary Care
Investor Presentation PEER ONLINE PROVIDES CLINICAL DECISION SUPPORT FOR PRIMARY CARE 10 EEG securely uploaded to PEER Online Patient has EEG scan in Primary Care Office Patient EEG Compared to 40,000 data points in the PEER Online database Personalized PEER Report is generated by the artificial int
Slide 11: PEER Assisted Treatment Plans Achieve Better and Faster Results
Investor Presentation PEER ASSISTED TREATMENT PLANS ACHIEVE BETTER AND FASTER RESULTS 11 DEBATTISTA 2011 – PEER VS STAR - D 1 Quick Inventory of Depressive Symptomatology Self - Report (QIDS - SR) is a standard psychometric evaluation in patients with chronic major depression ; the lower the score t
Slide 12: Clinical Evidence for PEER
Investor Presentation 12 CLINICAL EVIDENCE FOR PEER Independent studies • 45 studies with 3 , 130 patients offer compelling evidence for QEEG biomarkers as simple, inexpensive predictors of patient response to specific antidepressants and likely treatment - related side effects (including suicidal i
Slide 13: What Doctors Say
Investor Presentation 13 WHAT DOCTORS SAY “Why are we treating an organ, the brain, without measuring the effect of our treatment on the organ? There are over 100 medications available for the treatment of behavioral disorders. The core problem is not that we need three more, the problem is that we
Slide 14: Improving Access to Care Through Arcadian Telepsychiatry
Investor Presentation 14 IMPROVING ACCESS TO CARE THROUGH ARCADIAN TELEPSYCHIATRY Arcadian provides a technology enabled tele behavioral health s olution through a network of social workers, therapists , nurse practitioners, and psychiatrists that are licensed throughout the United States. Turnkey C
Slide 15: Telemedicine Technology Platform Seamlessly Integrates with Clinics
Investor Presentation TELEMEDICINE TECHNOLOGY PLATFORM SEAMLESSLY INTEGRATES WITH CLINICS 15 Primary Care EHR Secure Video Scheduling Patient History E - Prescribing Visit Notes Patient Portal HL7 CCDA Manual Sync Arcadian Platform Behavioral Health Patient The Arcadian telemedicine technology platf
Slide 16: Differentiated Behavioral Health Technology and Services
Investor Presentation Behavioral Health Patient Arcadian Care Coordinator Arcadian Psychiatrist PEER Enabled Primary Care Tele - Therapy At PCP On Mobile At Home Telepsychiatry enabled Primary Care Clinic Arcadian Psychiatrist Consult Available Personalized Treatment Plan DIFFERENTIATED BEHAVIORAL H
Slide 17: Total Available Market
Investor Presentation TOTAL AVAILABLE MARKET 17 1. Roman D, Conlee K, Goldman Sachs Equity Research June 29, 2015, Internet of Things Vol 5 2. https://www.ahrq.gov/research/findings/factsheets/primary/pcwork1/index.html 3. https://fitsmallbusiness.com/what - is - an - eap - employee - assistance - p
Slide 18: Growth Strategy
Investor Presentation GROWTH STRATEGY 18 Organic Inorganic New Market Telepsychiatry Expansion within existing, large clients can drive significant revenue growth with low customer acquisition costs. Focus on expansion within primary care with a differentiated solution. Invest in sales, marketing, t
Slide 19: Recent Developments
Investor Presentation RECENT DEVELOPMENTS Recent developments illustrate highly scalable business model : x Partnered with Sanford Health to provide telepsychiatry services supporting outpatient primary care practices. x Launched telepsychiatry coverage for Memorial Hospital Gulfport to provide serv
Slide 20: 2019 Milestones
Investor Presentation 20 2019 MILESTONES 1 Expand partnership with Sanford Health to provide telebehavioral health and telepsychiatry services through Arcadian’s provider network for Sanford Health’s network of outpatient primary care practices. 2 Expand relationship with one of the nation’s leading
Slide 21: Capitalization
21 CAPITALIZATION Common Stock Issued and Outstanding (5/31/19) 12,700,016 Series A Preferred 550,000 Series A - 1 Preferred 500,000 Total Shares of Common Stock Underlying Issued Options 1,670,767 Total Shares of Common Stock Underlying Issued Warrants 6,269,673 Fully Diluted Shares Outstanding 21,
Slide 22: Summary
Investor Presentation 22 SUMMARY Enabling clinicians to deliver a personalized therapy solution with PEER and provide greater access to behavioral health clinicians through telemedicine while lowering the overall costs associated with untreated behavioral health conditions. • With telemedicine, we c
Slide 23: Emmaus Merger & Spinoff
Investor Presentation EMMAUS MERGER & SPINOFF • Announced merger and spinoff transaction with Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, in January 2019. • Emmaus will become a wholly owned subsidiary of MYnd Analytics in exchange for MYnd Analytics’ issuance of common st
Slide 24: About Emmaus
Investor Presentation ABOUT EMMAUS x Emmaus’ lead prescription product, Endari, demonstrated positive clinical results in a completed Phase 3 clinical trial for sickle cell disease and received FDA approval in July 2017 x Endari is indicated to reduce the acute complications of sickle cell disease i
Slide 25: Contact
Investor Presentation 25 CONTACT Robin L. Smith, MD, MBA, Chairman of the Board tel : 917 - 691 - 7409 email: robin@robinlsmith.com Patrick Herguth Chief Executive Officer tel: (949) 420 - 4400 email: pherguth@myndanalytics.com Don D’Ambrosio, Chief Financial Officer tel : email: da